GoodRx Holdings

GoodRx Holdings, Inc. operates a consumer-focused digital healthcare platform. The firm offers information and tools to help consumers compare prices for prescription drugs. It operates applications and websites that provide prices and discounts at local and mail-order pharmacies. The company was founded by in Trevor Bezdek and Douglas Hirsch Joseph in September 2015 and is headquartered in Santa Monica, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GoodRx reports Q4 revenue decline but anticipates growth opportunities

GoodRx's Q4 2022 performance showed a decline in revenue but improvements in adjusted EBITDA. The company's focus on deepening relationships, increasing savings, and leveraging data presents strengths. Challenges include financial impacts from the grocer issue and decisions on revenue streams. Opportunities lie in non-grocery retailers, pharma manufacturer solutions, and sales optimization.

GoodRx reports strong Q1 performance and anticipates growth opportunities

GoodRx's Q1 performance reflects growth and positive outlook for managed solutions segment, despite challenges in revenue moderation and deal timelines.
The company's strengths lie in its strong foundation, talented team, and unique marketplace value proposition, with opportunities for further growth and innovation.
Challenges include potential revenue impact from program moderation and deal delays, but regulatory proposals are not expected to significantly affect business operations.
Overall, GoodRx remains focused on driving volume growth, maintaining market leadership, and providing affordable prescriptions to consumers.

GoodRx exceeds Q2 guidance, focuses on growth and partnerships

GoodRx's Q2 2023 earnings call showcased strong financial performance, exceeding guidance and reporting net income driven by a release of valuation allowance.
The company's focus on growth, profitability, and strategic realignment positions it well for compounding growth in 2024 and beyond, emphasizing proactive retail partnerships and efficient customer service strategies.
While challenges in deprioritizing certain solutions and balancing marketing spend efficiency exist, opportunities in optimizing retailer partnerships, leveraging data analytics, and attracting new members without incremental spend are key for future success.
Overall, GoodRx's innovative approach, unique value proposition, and financial and operational strengths highlight its resilience and potential for sustained growth and profitability.

GoodRx reports revenue growth and eyes pharma solutions expansion

GoodRx reported solid Q3 performance with revenue growth and strong cash generation, focusing on margin improvement and bottom-line profitability.
Despite challenges in subscription revenue and one-time payments, the company is eyeing growth opportunities in ISP, pharma solutions, and marketing efforts.
Analyst questions addressed key areas like retail stability, revenue growth expectations, and margin dynamics, indicating investor interest in future prospects.
GoodRx's strategic focus on expanding services, enhancing pricing strategies, and market access programs positions it for continued growth and value creation.

GoodRx exceeds Q4 expectations, eyes growth through strategic initiatives

GoodRx's Q4 '23 performance reflects strong financials, operational resilience, and strategic focus on growth initiatives.
The company's success in saving consumers billions and expanding market reach positions it well for future opportunities.
Challenges such as system issues and market competition require ongoing attention and strategic planning.
Opportunities in scaling solutions, targeted marketing, and strategic partnerships can drive sustained growth and market leadership.

GoodRx reports solid Q1 performance, eyes margin expansion opportunities

GoodRx's Q1 2024 performance showcased revenue growth and strong EBITDA margins, supported by strategic capital deployment and cash reserves.
Challenges include PTR per MAC decline and addressing analyst inquiries on ISP growth and margin concerns.
Opportunities lie in upcoming Analyst Day insights, ISP performance enhancements, and driving margin expansion through operational efficiencies.
Overall, GoodRx anticipates sustained growth, margin improvement, and continued ISP expansion throughout the year.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

SANTA MONICA, Calif.--(BUSINESS WIRE)--GoodRx, Inc. (NASDAQ: GDRX), America's leading resource for healthcare savings, today released the results of a July 2021 internal survey of healthcare providers who utilize GoodRx showing the positive and strong relationships the company has with healthcare professionals. Findings indicate providers believe that using GoodRx improves patient access to medication and increases adherence, as well as reduces the administrative burden they face. Professional

New Internal Survey Shows Strength of Relationship Between GoodRx and Healthcare Providers

Big 5 Sporting Goods

Blink Charging

Arcimoto

Gogo

GSX Techedu Inc.

Intercept Pharma

Root

SmileDirectClub

Workhorse Group

We're seeing loads of interest from investors targeting short-squeeze stocks this week as meme rallies push several shares higher. The post Short-Squeeze Stocks: Top 10 Stocks With High Short Interest This Week appeared first on InvestorPlace.

Short-Squeeze Stocks: Top 10 Stocks With High Short Interest This Week

This disruptor is making it easy for consumers to find their prescriptions for the cheapest price.

Why GoodRx Is the Antidote to High Drug Prices

Align Technology

Intuitive Surgical

Given time, these companies might do a lot better than that.

3 Healthcare Stocks I Fully Expect to Double or More Within the Next 5 Years

SANTA MONICA, Calif., Aug. 26, 2021 (GLOBE NEWSWIRE) -- GoodRx Holdings Inc. (Nasdaq: GDRX), America's leading resource for healthcare savings, today announced that executives from the Company will be presenting at the following virtual investor conferences:

GoodRx to Present Virtually at Upcoming Investor Conferences

Twitter

Although these companies are coming off strong quarterly results, I still wouldn't invest in them.

2 Overpriced Stocks That Investors Should Avoid

GoodRx reported earnings recently, on August 12, 2021. GoodRx beat on both the top and bottom line while delivering strong third-quarter guidance, sending the stock up over 14% on the 12th.

GoodRx: David Becomes Goliath

The discount-medications specialist looks set to benefit from a return to the doctor's office for many customers.

Why GoodRx Holdings Trounced the Market Today

GoodRx's (GDRX) Management Team on Q2 2021 Results - Earnings Call Transcript

Healthcare is rife with frictions – for patients, certainly, grappling with the increasing burdens of high deductibles, high drug costs and the responsibility for a growing percentage of financial liability tied to their care. In the app-driven economy, that digital front door can be key to finding discounts that can ease the financial burden in […]

GoodRx Reports Spike In Subscribers Seeking Drug Discounts

GoodRx Monthly Active Consumers Grow 36 Pct YOY

MediaCo Holding Inc.

Piedmont Lithium

Origin Agritech

Support.com

Tattooed Chef

Exela Technologies

If you're feeling contrarian and want to take the battle to the bears, these short squeeze stocks could drive up massive profits. The post 7 Short Squeeze Stocks for Contrarians Who Want to Live Dangerously appeared first on InvestorPlace.

7 Short Squeeze Stocks for Contrarians Who Want to Live Dangerously

SANTA MONICA, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- GoodRx Holdings, Inc. (Nasdaq: GDRX), America's leading resource for healthcare savings, has released its second quarter 2021 financial results and posted a letter to shareholders on the Overview page of its investor relations website at https://investors.goodrx.com .

GoodRx Releases Second Quarter 2021 Financial Results

Potential to provide approximately $15 million a year in savings for life-enhancing medications Potential to provide approximately $15 million a year in savings for life-enhancing medications

CORRECTING and REPLACING - GoodRx and Boehringer Ingelheim Announce Joint Effort to Deliver Affordability Solutions to Patients

Clover Health Investments

The regulatory environment could shift beneath their feet in the near future.

These 2 Healthcare Innovators Might Soon Face a Reckoning

GoodRx and Boehringer Ingelheim Announce Joint Effort to Deliver Affordability Solutions to Patients

GoodRx has struck a deal with Surescripts on the Real-Time Prescription Benefit electronic drug discount pricing program to help uninsured patients and those who can't get pricing information from their health plans, according to a press release. About one-third of Americans have skipped filling a prescription for an existing chronic condition at least once because […]

GoodRX, Surescripts Team For Real-Time Drug Discounts

SANTA MONICA, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- GoodRx (NASDAQ: GDRX), America's leading resource for healthcare savings, today announced that it has entered into an agreement with Surescripts , the nation's leading health information network, to deliver drug discount price information to prescribers using Surescripts Real-Time Prescription Benefit when prescribing medications for uninsured patients and patients whose price information isn't already available from their PBM or health plan. Surescripts Real-Time Prescription Benefit delivers cost information in the electronic workflow so prescribers can make more informed decisions and address patient prescription cost concerns at the point of care.

GoodRx Announces Agreement with Surescripts to Provide Real-Time Drug Discount Pricing in Electronic Health Records

A new consumer survey finds GoodRx discounts boost sales for retailers through new foot traffic A new consumer survey finds GoodRx discounts boost sales for retailers through new foot traffic

GoodRx Savings Increase Pharmacy Visits and Customer Loyalty For Retailers

GoHealth, Inc.

CHICAGO and SANTA MONICA, Calif., Aug. 2, 2021 /PRNewswire/ -- GoHealth, Inc. (GoHealth) (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, and GoodRx, Inc. (NASDAQ: GDRX), America's leading resource for healthcare savings, today announced an exclusive agreement to bring GoHealth's Medicare enrollment and engagement solutions directly to GoodRx users on the GoodRx platform.

GoHealth and GoodRx Announce Exclusive Medicare Agreement

Shares of GoodRx have tumbled 20% this year in spite of considerable progress toward the company's ambitious goals. Healthcare is a $4 trillion annual market, and ripe for technology disruption.

GoodRx: The Growth Runway Is Long

Slowing user growth and the long shadow of a competitor dampened enthusiasm for the stock.

Why Shares of GoodRx Fell 10.7% in the First Half of 2021

Academy Sports and Outdoors

Carver Bancorp

GEO Group

MicroStrategy Incorporated

Ocugen, Inc.

We're taking a look at some of the lesser-known short-squeeze stocks popular with retail investors that should be on your radar. The post 9 Lesser-Known Short-Squeeze Stocks Popular With Retail Investors appeared first on InvestorPlace.

9 Lesser-Known Short-Squeeze Stocks Popular With Retail Investors

DoorDash

"We're focused on trying to serve not just American consumers, but organizations [and] employers" in getting affordable prescriptions, CEO Doug Hirsch said.

GoodRx to assist gig workers in pharmaceutical drug discounting deal with DoorDash

 Clene Nanomedicine

iRobot

Tanger Factory Outlet Centers

Sequential Brands Group

Upstart Holdings

These shares are among the stocks with the most short sell positions The post 7 Short-Squeeze Stocks To Buy In July For Contrarian Investors appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now It doesn't matter if you have $500 in savings or $5 million.

7 Short-Squeeze Stocks To Buy In July For Contrarian Investors

News for GoodRx Holdings Stock (GDRX)